Fig. 3From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trialsMean percent change (± SD) from baseline in bone turnover markers (Urine NTX (a), Urine CTX (b) and Serum BAP (c)) in receiving risedronate. Patients were stratified into three cohorts by eGFR in baseline, and the mean percent change in bone turnover markers in each cohort was shown. *p < 0.001, significantly different from baselineBack to article page